TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse modelSebastian Johannes Schober(München Klinik Schwabing), Uwe Thiel(München Klinik Schwabing)Frontiers in ImmunologyJanuary 22, 202410.3389/fimmu.2024.1330868Cited by 5SaveCiteExport RISWatch citationsRelated PapersEwing Sarcoma-Derived Extracellular Vesicles Impair Dendritic Cell Maturation and Function|Cells|2021|30YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells|Frontiers in Oncology|2024|1